An article by the Center for Science in the Public Interest classified all available published placebo-controlled trials of SSRI’s in children and adolescents as industry-funded or non-industry funded. The results showed that 90% of industry-funded trials in the published literature were reported as positive, while only 55.6% of non-industry-funded trials were positive.
当然，关注儿童临床案例的不止英国医药与健康产品管理委员会(MHRA)一家。《英国医学杂志》(《British Medical Journal》)2004年4月称，关于SSRI临床案例的大部分论文都夸大了它的实际效用，而对它的危险性却轻描淡写。SSRI’s控制安慰剂用量后对儿童和青少年进行试验，公众利益科学中心(Center for Science in the Public Interest)对已发表的这些实验进行分类后，发表文章称，这种试验可分为两种，一种为厂商赞助性试验，另一种为非厂商赞助性试验。前者的90%在社会公共刊物中被正面报道，与之相比，正面报道非厂商赞助性试验的概率只有55.6%。